Prognostic significance of BLK expression in R-CHOP treated diffuse large B-cell lymphoma
- Author:
Soyeon CHOI
1
;
Yoo Jin LEE
;
Yunsuk CHOI
;
Misung KIM
;
Hyun-Jung KIM
;
Ji Eun KIM
;
Sukjoong OH
;
Seoung Wan CHAE
;
Hee Jeong CHA
;
Jae-Cheol JO
Author Information
- Publication Type:Original Article
- From:Journal of Pathology and Translational Medicine 2022;56(5):281-288
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:The aim of the present study was to evaluate the prognostic significance of B-cell lymphocyte kinase (BLK) expression for survival outcomes in diffuse large B-cell lymphoma (DLBCL) patients treated with R-CHOP.
Methods:We retrospectively analyzed the medical records of 89 patients from two tertiary referral hospitals. The expression of BLK, SYK, and CDK1 were evaluated in a semiquantitative method using an H-score, and the proportions of BCL2 and C-MYC were evaluated.
Results:A total of 89 patients received R-CHOP chemotherapy as a first-line chemotherapy. The expression rates of BLK in tumor cells was 39.2% (n = 34). BLK expression status was not significantly associated with clinical variables; however, BLK expression in tumor cells was significantly associated with the expression of both C-MYC and BCL2 (p = .003). With a median follow-up of 60.4 months, patients with BLK expression had significantly lower 5-year progression-free survival (PFS) and overall survival rates (49.8% and 60.9%, respectively) than patients without BLK expression (77.3% and 86.7%, respectively). In multivariate analysis for PFS, BLK positivity was an independent poor prognostic factor (hazard ratio, 2.208; p = .040).
Conclusions:Here, we describe the clinicopathological features and survival outcome according to expression of BLK in DLBCL. Approximately 39% of DLBCL patients showed BLK positivity, which was associated as a predictive marker for poor prognosis in patients who received R-CHOP chemotherapy.
